FIERCE-HN: A Multicenter, Randomized, Placebo-Controlled, Phase 3 Study of Ficlatuzumab plus Cetuximab in Pts W/ Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

被引：0
|
作者：
Bauman, J. [1 ]
Allman, K. [2 ]
Haddad, R. I. [3 ]
机构：
[1] George Washington Univ, Sch Med & Hlth Sci, Med Oncol, Washington, DC USA
[2] AVEO Oncol, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3609
引用
收藏
页码：E734 / E734
页数：1
相关论文
共 50 条
  • [1] FIERCE-HN: A Multicenter, Randomized, Placebo-controlled, Phase 3 Study of ficlatuzumab plus cetuximab in pts w/recurrent or Metastatic (R/M) HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
    Bauman, J.
    Allman, K.
    Haddad, R. I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E36 - E36
  • [2] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Bauman, J. E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] ATHENA: A multicenter phase II of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) - The HPV-negative cohort
    Fayette, J.
    Saada, E. B.
    DeMontfort, A.
    Karabajakian, A.
    Neidhardt, E. M.
    Borel, C.
    Burgy, M.
    Carinato, H.
    Delord, J-P.
    Betrian, S.
    Toussaint, P.
    Chatellier, T.
    Iharidon, T.
    Garin, G.
    Bernardin, M.
    Jaouen, L.
    Sondarjee, I.
    Perol, D.
    Blay, J-Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S851 - S852
  • [4] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Roe, Denise
    Saba, Nabil F.
    Bauman, Jessica Ruth
    Kaczmar, John M.
    Burtness, Barbara
    Muzaffar, Jameel
    Julian, Ricklie Ann
    Wang, Steven
    Bearelly, Shethal
    Baker, Audrey
    Steuer, Conor Ernst
    Bhatia, Aarti K.
    Giri, Anshu
    Caulin, Carlos
    Stabile, Laura P.
    Centuori, Sara
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Duwuri, Umamaheswar
    Ferris, Robert L.
    Ohr, James
    Gooding, William E.
    Kim, Seungwon
    Johnson, Jonas Talmadge
    Grandis, Jennifer R.
    Stabile, Laura P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn, Lara
    Ho, Alan Loh
    Eng, Juliana
    Michel, Loren S.
    Fetten, James Vincent
    Warner, Elizabeth
    Kriplani, Anuja
    Zhi, Wanqing Iris
    Ng, Kenneth K.
    Haque, Sofia
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
    Geiger, J. L.
    Egloff, A. M.
    Ohr, J.
    Stabile, L.
    Gooding, W.
    Flaherty, J.
    Gibson, M.
    Grandis, J.
    Bauman, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 930 - 930
  • [8] Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Garralda, E.
    Villacampa Javierre, G.
    Feliu, B.
    Martinez, S.
    Gutierrez, R.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 59 - 59
  • [9] A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
    Ho, A. L.
    Adkins, D. R.
    Hanna, G. J.
    Bruce, J.
    Ahn, M. J.
    Docampo, L. Iglesias
    Kang, H.
    Wong, D. J.
    Psyrri, A.
    Gillison, M.
    Brana, I.
    Liu, Y. C.
    Hsieh, C. Y.
    Hong, M. H.
    Zhang, Z.
    Balsara, B.
    Saunders, A.
    Hernandez, A. Gasco
    Dale, S.
    Haddad, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S1286 - S1287
  • [10] SAFETY AND EFFICACY OF CISPLATIN PLUS 5-FU AND CETUXIMAB IN HPV-POSITIVE AND HPV-NEGATIVE RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN): ANALYSIS OF THE PHASE III EXTREME TRIAL
    Psyrri, A.
    Licitra, L.
    De Blas, B.
    Celik, I.
    Vermorken, J. B.
    ANNALS OF ONCOLOGY, 2012, 23 : 334 - 335
12345